Investigating a short course treatment for preventing tuberculosis in healthy individuals
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
This study is testing a new, shorter treatment for preventing tuberculosis using rifapentine and isoniazid, and it's for people who don't have HIV, aiming to make it easier and safer for them to stick to their therapy.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10863977 on NIH RePORTER |
What this research studies
This research focuses on evaluating the safety and tolerability of a new short course treatment regimen for tuberculosis prevention, specifically using rifapentine and isoniazid. The study aims to determine how well this treatment works in preventing tuberculosis in individuals who do not have HIV. By comparing this new regimen to traditional longer treatments, the research seeks to improve adherence and reduce side effects, making it easier for patients to complete their therapy. Participants will be monitored for any adverse effects and overall effectiveness of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are healthy individuals aged 21 years and older who are at risk for tuberculosis but do not have HIV.
Not a fit: Patients who are currently infected with tuberculosis or those who have HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer way to prevent tuberculosis, potentially saving lives and reducing the burden of the disease.
How similar studies have performed: Previous research has shown success with similar short-course treatments for tuberculosis, indicating a promising approach to prevention.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Chaisson, Richard E. — Johns Hopkins University
- Study coordinator: Chaisson, Richard E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.